AAIC event – Biogen and Eisai move to consolidate beta-amyloid lead

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 17, 2018 at 11:32 PM.

  1. #1 cafead, Jul 17, 2018 at 11:32 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,028
    Likes Received:
    3
    via The revelation that a mid-stage trial of Biogen/Eisai’s beta-amyloid MAbBAN2401 had shown glimmers of hope has fired up the Alzheimer’s world and, along with it, the stock markets. Now comes the tricky bit: providing hard data to convince investors that BAN2401 could be clinically relevant.

    article source
     
    Quote

Reply to Thread